Two Patients Now Exceeding 1 Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial September 22, 2024
Patient Recruitment Discontinued in LUNGVAC Trial Investigating UV1 Combined with Checkpoint Inhibitor Therapy in NSCLC September 18, 2024
First patient enrolled in triple combination arm of BI-1206, rituximab and Calquence® for the treatment of NHL September 18, 2024
Global Launch of Artemia Ph 3 Registration Study for Cancer Vaccine Tedopi® in 2L NSCLC Cancer Announced September 18, 2024
Trials evaluating ONCT-534 in metastatic CRPC & ONCT-808 in BCL discontinued to explore strategic alternative September 18, 2024
First patient dosed in Investigator-initiated Ph Ib study of iadademstat in 1L AML September 18, 2024
IDMC recommends continuing Ph 3 trial (IOB-013/KN-D18) of IO102-IO103 following a per-protocol interim analysis September 10, 2024
GBM program of INB-200 and INB-400 to be suspended; AML program of INB-100 to be prioritized September 10, 2024
First patient enrolled in Ph 3 SOHO-02 trial of BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations September 3, 2024
Enrollment Completed in Ph 2 I-SPY 2 Arm Evaluating Lasofoxifene in Neoadjuvant Breast Cancer Setting September 3, 2024
Nadunolimab clinical trials in AML/MDA and TNBC to be initiated in Q4 2024 and H2 2025, respectively September 3, 2024
FAILED TRIAL: PRECISION1 trial of nab-sirolimus in patients with solid tumors with TSC1/2 inactivating mutations to be halted as study unlikely to exceed the efficacy threshold August 27, 2024
Randomized controlled trial of Nana-val in EBV-positive PTCL patients planned to begin in the second half of 2025 to support potential registration August 27, 2024
First patient dosed in trial of MOMA-313 in patients with cancers carrying mutations in DNA repair genes August 27, 2024
Enrollment Completed in China GC/GEJ Pivotal Ph 2 Clinical Trial of Claudin18.2 CAR T (Satri-cel) August 27, 2024
First Patient dosed in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer August 27, 2024
